Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Technology ID
TAB-3867

A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis

E-Numbers
E-058-2009-0
Lead Inventors
Gildersleeve, Jeffrey
Co-Inventors
Li, Zhitao
Li, Qian
Anver, Miriam
Butcher, Donna
Applications
Research Materials
Therapeutic Areas
Oncology
Development Stages
Discovery
Lead IC
NCI
ICs
NCI
Leidos

Cervical cancer is one of the most common cancers among women worldwide. Currently, physical descriptors such as tumor size and depth are the primary factors used for deciding the course of treatment. Despite significant efforts to identify prognostic biochemical markers or therapeutic targets to improve diagnosis and treatment, none have achieved routine clinical use. An example of one previously identified biomarker is the Tn antigen, a carbohydrate moiety composed of a GalNAc residue linked to serine or threonine. Previous studies examining Tn antigen levels present in cervical cancer tumors have produced conflicting results. The inventors discovered that this phenomenon is a direct result of using antibodies that are cross reactive to carbohydrates terminating in GalNAcal-3Gal or GalNAca1-6Gal. To precisely determine which carbohydrate antigen correlates with cervical cancer formation, the investigators produced a series of antibodies with high degrees of specificity for structurally distinct variants of the Tn antigen. The results show that relative to other carbohydrate antigens examined, GalNAca1-3Gal is expressed at high levels in squamous carcinomas of the cervix.  Importantly, expression levels of GalNAcal-3Gal have a statistically significant correlation with 5-year survival rates. 

Researchers at NCI developed antibodies with high specificity for GalNAca1-3Gal, which can be used to both diagnose cervical cancer and as a prognostic tool. In addition to cervical cancer, elevated GalNAc1-3Gal is present in a variety of other human carcinomas, including squamous cell carcinoma, esophageal cancer, laryngeal cancer, and skin cancer. 

Competitive Advantages:

  • Only monoclonal antibody known to bind the GalNAca1-3Gal antigen but no other closely related structures, including blood group A, the Forssman antigen, and the Tn antigen. 
  • Binds various human tumor samples via immunohistochemistry
  • The antibody is a rabbit IgG. 

Commercial Applications:

  • Cervical cancer diagnostics and prognosis 
  • Research tool
  • Immunohistochemical staining of a variety of carcinomas including cervical, larynx, and skin squamous cell carcinomas
Licensing Contacts
Nguyen-Antczak, Lauren
lauren.nguyen-antczak@nih.gov